Zucara Therapeutics, a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with diabetes, recently announced additional funding of US$2 million from JDRF, the leading global Type 1 diabetes research and advocacy organization. The funding will support Zucara’s planned Phase 2a study aimed at showing prevention of hypoglycemia in people with Type 1 diabetes.
Zucara Therapeutics is an OBIO® member, is part of OBIO’s Workforce Development programs and presented at the OBIO® Investment Summit.